Free Trial

Pliant Therapeutics Q1 2024 Earnings Report

Pliant Therapeutics logo
$1.47 -0.04 (-2.65%)
As of 03/28/2025 04:00 PM Eastern

Pliant Therapeutics EPS Results

Actual EPS
-$0.78
Consensus EPS
-$0.76
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Pliant Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pliant Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

Pliant Therapeutics Earnings Headlines

Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
See More Pliant Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pliant Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pliant Therapeutics and other key companies, straight to your email.

About Pliant Therapeutics

Pliant Therapeutics (NASDAQ:PLRX), a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

View Pliant Therapeutics Profile

More Earnings Resources from MarketBeat